The Week in Review: April 21, 2017 – April 28, 2017

Friday, April 28, 2017 News Recap Canada New Canadian Testing Guidelines Released: On April 24, 2017, The Canadian Task Force on Preventative Health Care (CTFPHC) published its HCV Screening Guidelines in the CMAJ. The guidelines make the recommendation to continue screening those with known risk factors, but does not include a recommendation to screen the age cohort born between 1945-1975, which has been recommended by many of Canada’s top liver sp...

AbbVie takes aim at Gilead and BMS with 8-week hep C treatment

AbbVie is aiming to steal sales from hep C drugs from Gilead and BMS with a new combination offering a shorter, eight-week treatment for the most difficult-to-treat form of the disease. Results presented at the International Liver Congress (ILC) in Amsterdam showed 95% of genotype 3 patients on its pan-genotypic regimen of glecaprevir+pibrentasvir were free of disease, 12 weeks after completing an eight-week treatment course. The results were based on

U.S.: AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

 Breakthrough Therapy Designation granted based on Phase 2 clinical data for genotype 1 (GT1) patients who failed previous therapy with direct-acting antivirals (DAAs)  Currently in Phase 3 clinical trials, glecaprevir/pibrentasvir (G/P) is an investigational, pan-genotypic regimen being evaluated for the treatment of chronic hepatitis C virus (HCV) genotypes 1-6  Breakthrough Therapy Designation is granted to investigational treatments for seri...